ABEO7:30 AMAbeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business UpdatePresentation / Abstract • Phase 3abeonatherapeutics.com
ABEO7:30 AMAbeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026abeonatherapeutics.com
ABEO7:30 AMCMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®abeonatherapeutics.com
ABEO7:30 AMAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)abeonatherapeutics.com
ABEO7:30 AMCincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®abeonatherapeutics.com
ABEO7:30 AMAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)abeonatherapeutics.com
ABEO8:30 AMAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)abeonatherapeutics.com
ABEO8:30 AMAbeona Therapeutics® Announces Participation in Upcoming Investor Conferencesabeonatherapeutics.com